Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC

By Kim C.-K.   Choi E.-J.   Choi S.-H.   Park J.-S.   Haider K.H.   Ahn W.S.  

Gynecologic Oncology, Vol. 90, Iss. 2, 2003-08 ,pp. : 265-272

Elsevier

Access to resources Recommend Favorite

A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells

By Kanamori Y.   Kigawa J.   Minagawa Y.   Irie T.   Oishi T.   Shimada M.   Takahashi M.   Nakamura T.   Sato K.   Terakawa N.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1802-1806

Elsevier

Access to resources Recommend Favorite

Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin

By Pagliaro L.C.   Keyhani A.   Liu B.   Perrotte P.   Wilson D.   Dinney C.P.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 456-462

Elsevier

Access to resources Recommend Favorite

The p53-deficient mouse: a model for basic and applied cancer studies

By Donehower L.A.  

Seminars in Cancer Biology, Vol. 7, Iss. 5, 1996-10 ,pp. : 269-278

Academic Press

Access to resources Recommend Favorite

In VivoStudies of Adenovirus-Based p53 Gene Therapy for Ovarian Cancer

By von Gruenigen V.E.   Santoso J.T.   Coleman R.L.   Muller C.Y.   Miller D.S.   Mathis J.M.  

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 197-204

Elsevier

Access to resources Recommend Favorite